Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
SINHCAF pseudogene 2 (SINHCAFP2) is a *pseudogene* and, by definition, is a DNA sequence in the human genome that resembles the parental SINHCAF gene but does not encode a functional protein due to disabling mutations or deletions[1][3][5][7][9]. Pseudogenes arise from gene duplication or retrotransposition events and are usually nonfunctional, lacking regulatory elements or containing mutations such as frameshifts or premature stop codons. Unlike the parental SINHCAF gene (which encodes a subunit of the Sin3A histone deacetylase complex involved in transcriptional repression and epigenetic regulation[2][4]), SINHCAFP2 does not produce a functional product and is not considered a therapeutic target. Pseudogenes may occasionally have regulatory roles in gene expression, but there is no evidence supporting such a role for SINHCAFP2[3][7][9]. It is not a drug target, does not have known disease associations, and is not used as a biomarker or for patient selection. Summary of key issues: - SINHCAFP2 is a *pseudogene*, not a protein-coding gene or a classical drug target[1][5][7][9]. - There is no evidence it is therapeutically actionable. - There is no established physiological or disease role, nor are there known drug interactions for this locus. If you intended to refer to the functional SINHCAF gene (not its pseudogene), please specify, as that gene encodes a protein involved in epigenetic and transcriptional regulation[2][4].
none
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on SINHCAF pseudogene 2 (SINHCAFP2).